A retrospective series found a 75% response rate adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer, said Susana Campos, MD, MPH.
Susana M. Campos, MD, MPH
Advertisement
Articles by Susana M. Campos, MD, MPH
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
Novel Cancer Vaccine Meets Primary, Secondary End Points in Resected Melanoma
2
Choosing Between Approved Frontline Metastatic Pancreatic Cancer Regimens
3
ccRCC PET Imaging Agent Earns FDA Breakthrough Therapy, Fast Track Statuses
4
Who Are The Key Candidates to Receive Subcutaneous Amivantamab for HNSCC?
5